[1]李妹玲.肝癌消融术后局部复发与早期复发危险因素的Meta分析[J].医学信息,2024,37(02):28-34.[doi:10.3969/j.issn.1006-1959.2024.02.005]
　LI Mei-ling.Meta-analysis of Risk Factors for Local Recurrence and Early Recurrence After Ablation Procedure of Liver Cancer[J].Journal of Medical Information,2024,37(02):28-34.[doi:10.3969/j.issn.1006-1959.2024.02.005]
点击复制

肝癌消融术后局部复发与早期复发危险因素的Meta分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年02期
页码:
28-34
栏目:
医学数据科学
出版日期:
2024-01-15

文章信息/Info

Title:
Meta-analysis of Risk Factors for Local Recurrence and Early Recurrence After Ablation Procedure of Liver Cancer
文章编号:
1006-1959（2024）02-0028-07
作者:
李妹玲
（重庆医科大学附属永川医院放射科，重庆 402160）
Author(s):
LI Mei-ling
(Department of Radiology,Yongchuan Hospital Affiliated to ChongQing Medical University,Chongqing 402160,China)
关键词:
肝癌; 消融; 局部复发; 早期复发
Keywords:
Liver cancer; Ablation; Local recurrence; Early recurrence
分类号:
R735.7
DOI:
10.3969/j.issn.1006-1959.2024.02.005
文献标志码:
A
摘要:
目的 系统评价肝癌单纯消融术后局部复发与早期复发（术后1年内）的危险因素。方法 计算机检索CNKI、WanFang Data、VIP、Web of science、PubMed、EMbase、SinoMed、The Cochrane Library数据库，搜集有关肝癌消融术后复发危险因素的病例-对照研究和队列研究，检索时限均为建库至2022年5月。由2名研究者独立筛选文献、提取资料并评价纳入研究的偏倚风险后，采用RevMan5.3软件进行Meta分析。结果 其纳入22篇文献，发表时间为2012-2022年，根据纳入标准剔除2篇，最终纳入14篇研究局部复发、6篇研究早期复发的文献，分别包括5836例、728例患者。Meta分析结果显示，局部复发的危险因素包括肿瘤直径＞2 cm（RR=1.92，95%CI：1.54~2.38，P＜0.000 01）、肿瘤靠近大血管（RR=2.36，95%CI：1.79~3.11，P＜0.000 01）、肿瘤靠近横膈（RR=2.50，95%CI： 1.61~3.87，P＜0.0001），其它危险因素包括消融安全边界不足、ADC图低信号；早期复发的危险因素包括肿瘤数≥2个（OR=4.02，95%CI：2.25~7.17，P＜0.000 01）、甲胎蛋白（AFP）＞400 ng/ml（OR=4.19，95%CI：1.47~11.93，P=0.007）、白蛋白（ALB）≤35 g/L（OR=0.36，95%CI：0.16~0.79，P=0.01）。结论 严格控制消融的纳入标准，对于肿瘤数量多、直径大、高风险位置、肿瘤标志物高、结合影像学高危征象，可行联合治疗或者手术切除，以减少肝癌术后复发率。
Abstract:
Objective To systematically evaluate the risk factors of local recurrence and early recurrence (within 1 year after operation) after ablation procedure of liver cancer.Methods CNKI, WanFang Data, VIP, Web of science, PubMed, EMbase, SinoMed and The Cochrane Library databases were searched by computer to collect case-control studies and cohort studies on the risk factors of recurrence after ablation procedure of liver cancer from the database construction to May 2022. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Then, meta-analysis was performed using RevMan 5.3 software.Results 22 articles were included, published from 2012 to 2022, and 2 articles were excluded according to the inclusion criteria. Of 14 articles about local recurrence and 6 articles about early recurrence were included, with 5836 patients and 728 patients respectively. The results of Meta-analysis showed that the risk factors of local recurrence included tumor diameter>2 cm (RR=1.92,95%CI:1.54-2.38,P<0.000 01), tumor near large blood vessels (RR=2.36,95%CI:1.79-3.11,P<0.000 01), tumor near the diaphragm (RR=2.50,95%CI:1.61-3.87,P<0.000 1), and other risk factors included insufficient ablation safety boundary and low signal of ADC map. The risk factors for early recurrence included the number of tumors≥2 (OR=4.02,95%CI:2.25-7.17,P<0.000 01), AFP>400 ng/ml (OR=4.19,95%CI:1.47-11.93,P=0.007), ALB≤35 g/L (OR=0.36,95%CI:0.16-0.79,P=0.01).Conclusion Strictly control the inclusion criteria of ablation. For the large number of tumors, large diameter, high-risk location, high tumor markers and high-risk signs in combination with imaging, combined treatment or surgical resection is feasible to reduce the postoperative recurrence rate of liver cancer.

参考文献/References:

[1]邓俊,周颜,杨美蓉,等.早期肝癌射频消融术后复发时间的影响因素[J].肝脏,2019,24(4):438－442.[2]Zhang NN,Lu W,Cheng XJ,et al.High-powered microwave ablation of larger hepatocellular carcinoma: evaluation of recurrence rate and factors related to recurrence[J].Clin Radiol,2015,70(11):1237-1243.[3]李柱,廖信芳,吕海钠.超声引导下射频消融术治疗肝癌术后局部复发因素分析[J].广州医药,2020,51(6):79-82,89.[4]韩融诚.基于磁共振成像预测肝细胞癌射频消融后复发的价值研究[D].北京:中国医学科学院,2021.[5]刘宜翔,牛坚.微波消融治疗肝癌后局部肿瘤进展的危险因素[J].蚌埠医学院学报,2021,46(4):491-498.[6]Norris JM,Simpson BS,Ball R,et al.A Modified Newcastle-Ottawa Scale for Assessment of Study Quality in Genetic Urological Research[J].Eur Urol,2021,79(3):325-326.[7]Kim JS,Kim W,So YH,et al.Topographical impact of hepatitis B-related hepatocellular carcinoma on local recurrence after radiofrequency ablation[J].J Clin Gastroenterol,2014,48(1):66-72.[8]An C,Wu S,Huang Z,et al.A novel nomogram to predict the local tumor progression after microwave ablation in patients with early-stage hepatocellular carcinoma: A tool in prediction of successful ablation[J].Cancer Med,2020,9(1):104-115.[9]Lee MW,Kang D,Lim HK,et al.Updated 10-year outcomes of percutaneous radiofrequency ablation as first-line therapy for single hepatocellular carcinoma <3 cm:emphasis on association of local tumor progression and overall survival[J].Eur Radiol,2020,30(4):2391-2400.[10]Kono M,Inoue T,Kudo M,et al.Radiofrequency ablation for hepatocellular carcinoma measuring 2 cm or smaller: results and risk factors for local recurrence[J].Dig Dis,2014,32(6):670-677.[11]Toshimori J,Nouso K,Nakamura S,et al.Local recurrence and complications after percutaneous radiofrequency ablation of hepatocellular carcinoma: a retrospective cohort study focused on tumor location[J].Acta Med Okayama,2015,69(4):219-226.[12]Mori Y,Tamai H,Shingaki N,et al.Signal intensity of small hepatocellular carcinoma on apparent diffusion coefficient mapping and outcome after radiofrequency ablation[J].Hepatol Res,2015,45(1):75-87.[13]Kim YS,Lim HK,Rhim H,et al.Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors[J].J Hepatol,2013,58(1):89-97.[14]Hu Z,Yu N,Wang H,et al.Pre-radiofrequency ablation MRI imaging features predict the local tumor progression in hepatocellular carcinoma[J].Medicine (Baltimore),2020,99(52):e23924.[15]Laimer G,Schullian P,Jaschke N,et al.Minimal ablative margin (MAM) assessment with image fusion: an independent predictor for local tumor progression in hepatocellular carcinoma after stereotactic radiofrequency ablation[J].Eur Radiol,2020,30(5):2463-2472.[16]Koda M,Tokunaga S,Miyoshi K,et al.Ablative margin states by magnetic resonance imaging with ferucarbotran in radiofrequency ablation for hepatocellular carcinoma can predict local tumor progression[J].J Gastroenterol,2013,48(11):1283-1292.[17]覃肖溪,杨红,何云,等.肝癌射频消融治疗后疗效及影响因素分析[J].广西医科大学学报,2013,30(4):587-590.[18]高君蓉,张雪君,朱晓琳.肝细胞肝癌射频消融后肿瘤局部进展危险因素分析[J].医学理论与实践,2018,31(23):3533-3535.[19]韩浩,陈敏华,杨薇,等.肝细胞癌射频消融后局部肿瘤进展多因素分析[J].中华超声影像学杂志,2012,21(2):128-132.[20]卢裕,卢钦荣,刘志浩.早期单发肝癌患者消融术后早期复发的影响因素研究[J].黑龙江医药,2021,2021,34(4):913-915.[21]扈彩霞,郑加生,林伟,等.原发性肝癌微波消融术后早期复发危险因素分析[J].临床肝胆病杂志,2015,31(2):228-231.[22]鹿宁宁,王海燕,张英华,等.BCLC 0～A期肝细胞癌消融术后早期复发转移危险因素分析[J].介入放射学杂志,2019,28(6):556-560.[23]Yang Y,Xin Y,Ye F,et al.Early recurrence after radiofrequency ablation for hepatocellular carcinoma: a multicenter retrospective study on definition, patterns and risk factors[J].Int J Hyperthermia,2021,38(1):437-446.[24]Imai K,Yamashita YI,Yusa T,et al.Microvascular Invasion in Small-sized Hepatocellular Carcinoma: Significance for Outcomes Following Hepatectomy and Radiofrequency Ablation[J].Anticancer Res,2018,38(2):1053-1060.[25]Takahashi H,Kahramangil B,Berber E.Local recurrence after microwave thermosphere ablation of malignant liver tumors: results of a surgical series[J].Surgery,2018,163(4):709-713.[26]Song KD,Lim HK,Rhim H,et al.Hepatic resection vs percutaneous radiofrequency ablation of hepatocellular carcinoma abutting right diaphragm[J].World J Gastrointest Oncol,2019,11(3):227-237.[27]Kang TW,Lim HK,Lee MW,et al.Aggressive Intrasegmental Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation: Risk Factors and Clinical Significance[J].Radiology,2015,276(1):274-285.[28]叶卫川,陈春妙,吴徐璐,等.肝细胞癌射频消融术后短期侵袭性复发与功能MRI的相关性研究[J].中华放射学杂志,2020,54(1):28-32.[29]Pecchi A,Besutti G,De Santis M,et al.Post-transplantation hepatocellular carcinoma recurrence: Patterns and relation between vascularity and differentiation degree[J].World J Hepatol,2015,7(2):276-284.[30]Xu Y,Shen Q,Wang N,et al.Percutaneous microwave ablation of 5-6 cm unresectable hepatocellular carcinoma: local efficacy and long-term outcomes[J].Int J Hyperthermia,2017,33(3):247-254.[31]Huang Z,Gu Y,Zhang T,et al.Nomograms to predict survival outcomes after microwave ablation in elderly patients (>65 years old) with early-stage hepatocellular carcinoma[J].Int J Hyperthermia,2020,37(1):808-818.[32]陈域,郭欣,陈芦斌,等.PLR和ASL水平与肝细胞癌消融术后早期复发转移的关系研究[J].临床肝胆病杂志,2021,24(1):81-85.

相似文献/References:

[1]修朋程,李 腾,李雅林,等.泰山山慈菇对小鼠肝癌的治疗作用及相关免疫机制研究[J].医学信息,2018,31(09):8.[doi:10.3969/j.issn.1006-1959.2018.09.003]
　XIU Peng-cheng,LI Teng,LI Ya-lin,et al.Study on the Therapeutic Effect and Mechanism of Taishan Mountain Mushroom on Liver Cancer in Mice[J].Journal of Medical Information,2018,31(02):8.[doi:10.3969/j.issn.1006-1959.2018.09.003]
[2]崔康健,杜成友.肝动脉化疗栓塞联合射频消融治疗肝癌的研究进展[J].医学信息,2018,31(09):16.[doi:10.3969/j.issn.1006-1959.2018.09.005]
　CUI Kang-jian,DU Cheng-you.Research Progress of Transcatheter Arterial Chemoembolization Combined with Radiofrequency Ablation for Liver Cancer[J].Journal of Medical Information,2018,31(02):16.[doi:10.3969/j.issn.1006-1959.2018.09.005]
[3]许 吉.基于知识图谱和专利地图的我国抗肝癌药物研发态势研究[J].医学信息,2018,31(21):19.[doi:10.3969/j.issn.1006-1959.2018.21.007]
　XU Ji.Research and Development Situation of Anti-liver Cancer Drugs in China Based on Knowledge Map and Patent Map[J].Journal of Medical Information,2018,31(02):19.[doi:10.3969/j.issn.1006-1959.2018.21.007]
[4]兰福全,李秀云,卢 斌.四种肿瘤标志物对肝癌诊断的临床意义[J].医学信息,2018,31(21):164.[doi:10.3969/j.issn.1006-1959.2018.21.048]
　LAN Fu-quan,LI Xiu-yun,LU Bin.The Clinical Significance of Four Tumor Markers in the Diagnosis of Liver Cancer[J].Journal of Medical Information,2018,31(02):164.[doi:10.3969/j.issn.1006-1959.2018.21.048]
[5]赵瑶瑶,高 川,胡佳杰.循环miRNA监测肝细癌的研究[J].医学信息,2019,32(08):48.[doi:10.3969/j.issn.1006-1959.2019.08.016]
　ZHAO Yao-yao,GAO Chuan,HU Jia-jie.Research on the Study of Circulating miRNA for Monitoring Hepatocellular Carcinoma[J].Journal of Medical Information,2019,32(02):48.[doi:10.3969/j.issn.1006-1959.2019.08.016]
[6]李 闯,叶劲松,刘 昕,等.ZBP-89与缺氧信号因子HIF-1α在肝癌细胞中的 相关性研究[J].医学信息,2019,32(15):74.[doi:10.3969/j.issn.1006-1959.2019.15.023]
　LI Chuang,YE Jin-song,LIU Xin,et al.Correlation between ZBP-89 and Hypoxia Signaling Factor HIF-1α in Hepatoma Cells[J].Journal of Medical Information,2019,32(02):74.[doi:10.3969/j.issn.1006-1959.2019.15.023]
[7]孙 逊.性化护理对肝癌患者CT引导下射频消融术后 负性情绪及生活质量的影响[J].医学信息,2019,32(17):187.[doi:10.3969/j.issn.1006-1959.2019.17.065]
　SUN Xun.Effect of Humanized Nursing on Negative Emotion and Quality of Life after CT-guided Radiofrequency Ablation in Patients with Liver Cancer[J].Journal of Medical Information,2019,32(02):187.[doi:10.3969/j.issn.1006-1959.2019.17.065]
[8]徐 蓓,魏霞丽,常艳琴.肝癌患者术后自我饮食管理体验的质性研究[J].医学信息,2019,32(20):180.[doi:10.3969/j.issn.1006-1959.2019.20.058]
　XU Bei,WEI Xia-li,CHANG Yan-qin.Qualitative Study of Postoperative Self-Catering Management Experience in Patients with Liver Cancer[J].Journal of Medical Information,2019,32(02):180.[doi:10.3969/j.issn.1006-1959.2019.20.058]
[9]田 明,常伟平.UbcH10在肝癌中的表达及其与预后的关系[J].医学信息,2019,32(12):77.[doi:10.3969/j.issn.1006-1959.2019.12.024]
　IAN Ming,CHANG Wei-ping.Expression of UbcH10 in Hepatocellular Carcinoma and Its Relationship with Prognosis[J].Journal of Medical Information,2019,32(02):77.[doi:10.3969/j.issn.1006-1959.2019.12.024]
[10]刘申颖,施彦卿,梅鹏飞,等.超声引导下经皮无水乙醇注射联合射频消融治疗中晚期肝癌的效果[J].医学信息,2019,32(22):87.[doi:10.3969/j.issn.1006-1959.2019.22.026]
　LIU Shen-ying,SHI Yan-qing,MEI Peng-fei,et al.Ultrasound-guided Percutaneous Ethanol Injection Combined with Radiofrequency Ablation for Advanced Hepatocellular Carcinoma[J].Journal of Medical Information,2019,32(02):87.[doi:10.3969/j.issn.1006-1959.2019.22.026]

更新日期/Last Update: 1900-01-01